NASDAQ:RNAC Cartesian Therapeutics (RNAC) Stock Price, News & Analysis $12.10 +0.10 (+0.83%) As of 10:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cartesian Therapeutics Stock (NASDAQ:RNAC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cartesian Therapeutics alerts:Sign Up Key Stats Today's Range$11.56▼$12.2150-Day Range$9.52▼$19.0752-Week Range$8.85▼$41.87Volume16,770 shsAverage Volume115,207 shsMarket Capitalization$313.47 millionP/E RatioN/ADividend YieldN/APrice Target$42.67Consensus RatingModerate Buy Company OverviewCartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.Read More… Cartesian Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreRNAC MarketRank™: Cartesian Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 639th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingCartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCartesian Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Cartesian Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cartesian Therapeutics are expected to decrease in the coming year, from $4.56 to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cartesian Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cartesian Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cartesian Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.47% of the float of Cartesian Therapeutics has been sold short.Short Interest Ratio / Days to CoverCartesian Therapeutics has a short interest ratio ("days to cover") of 25.2, which indicates bearish sentiment.Change versus previous monthShort interest in Cartesian Therapeutics has recently increased by 13.33%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCartesian Therapeutics does not currently pay a dividend.Dividend GrowthCartesian Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted28.47% of the float of Cartesian Therapeutics has been sold short.Short Interest Ratio / Days to CoverCartesian Therapeutics has a short interest ratio ("days to cover") of 25.2, which indicates bearish sentiment.Change versus previous monthShort interest in Cartesian Therapeutics has recently increased by 13.33%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment0.98 News SentimentCartesian Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Cartesian Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for RNAC on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Cartesian Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cartesian Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders57.90% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cartesian Therapeutics' insider trading history. Receive RNAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RNAC Stock News HeadlinesBrokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Price Target at $42.67April 30 at 2:09 AM | americanbankingnews.comCartesian Therapeutics management to meet with BTIGApril 26, 2025 | markets.businessinsider.comThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.May 1, 2025 | Stansberry Research (Ad)1RNAC : Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In...April 9, 2025 | benzinga.comMizuho Securities Sticks to Its Buy Rating for Cartesian Therapeutics (RNAC)April 9, 2025 | markets.businessinsider.comCartesian Therapeutics Shares Rise on Positive Phase 2b Trial ResultsApril 8, 2025 | marketwatch.comCartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis TrialApril 8, 2025 | globenewswire.comCartesian Therapeutics Announces New Employment Inducement GrantsApril 2, 2025 | globenewswire.comSee More Headlines RNAC Stock Analysis - Frequently Asked Questions How have RNAC shares performed this year? Cartesian Therapeutics' stock was trading at $17.91 on January 1st, 2025. Since then, RNAC stock has decreased by 33.0% and is now trading at $12.00. View the best growth stocks for 2025 here. How were Cartesian Therapeutics' earnings last quarter? Cartesian Therapeutics, Inc. (NASDAQ:RNAC) posted its earnings results on Thursday, August, 8th. The company reported $0.54 EPS for the quarter, beating the consensus estimate of ($0.81) by $1.35. The company had revenue of $33.45 million for the quarter, compared to the consensus estimate of $6 million. When did Cartesian Therapeutics' stock split? Cartesian Therapeutics shares reverse split on the morning of Friday, April 5th 2024. The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Cartesian Therapeutics' major shareholders? Top institutional shareholders of Cartesian Therapeutics include Bank of New York Mellon Corp (0.08%), Alps Advisors Inc. (0.07%) and Rhumbline Advisers (0.05%). Insiders that own company stock include Blaine Davis, Metin Kurtoglu and Milos Miljkovic. View institutional ownership trends. How do I buy shares of Cartesian Therapeutics? Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cartesian Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cartesian Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings8/08/2024Today4/30/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNAC Previous SymbolNASDAQ:RNAC CIK1453687 Webselectabio.com Phone617-923-1400Fax617-924-3454Employees64Year FoundedN/APrice Target and Rating Average Stock Price Target$42.67 High Stock Price Target$50.00 Low Stock Price Target$40.00 Potential Upside/Downside+255.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($52.83) Trailing P/E RatioN/A Forward P/E Ratio2.63 P/E GrowthN/ANet Income$-219,710,000.00 Net Margins-510.72% Pretax Margin-550.35% Return on EquityN/A Return on Assets-6.03% Debt Debt-to-Equity RatioN/A Current Ratio10.70 Quick Ratio10.70 Sales & Book Value Annual Sales$38.91 million Price / Sales7.99 Cash FlowN/A Price / Cash FlowN/A Book Value($82.38) per share Price / Book-0.15Miscellaneous Outstanding Shares25,907,000Free Float10,700,000Market Cap$310.88 million OptionableOptionable Beta0.55 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:RNAC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.